PEC sampling hits high grades at Itinga
Perpetual’s reconnaissance sampling has outlined the potential to advance multiple high-value commodities such as tin, niobium and titanium at its Itinga project.
Stockhead
Recce soars on phase II trial results
Recce Pharmaceuticals up ~9% after successful phase II clinical trial assessing efficacy and safety of R327G in patients with acute bacterial skin and skin structure infections.
GCM is cooling data centres with VHD heat sinks
Testing has shown that Green Critical Mineral’s VHD graphite has excellent thermal diffusivity properties that make it well suited for cooling AI data centres.
Recce gets Indonesian nod for phase III trial
Recce receives approval from Indonesia’s National Agency of Drug and Food Control for phase III trial of RECCE 327 topical gel in diabetic foot infections.
More Stories
Emyria shares gain on PTSD trial news
Psychedelic drug developer Emyria says the use of MDMA (Molly, or Esstacy) has a lasting effect for post-traumatic stress disorder sufferers
Pointerra, Hydrix led in Jan through DeepSeek storm
The Nasdaq hit new highs in January, then DeepSeek shook AI, but Pointerra and Hydrix led ASX tech through the storm.
ASX reached record high in January
The S&P/ASX 200 rose 5% in January to reach a new record high with AusQuest topping the winners list up 388% with discovery of a large-scale Peruvian copper prospect.
What’s hot at Mining Indaba 2025?
The four-day African mining-focused event will include presentations from mining experts, delegates and influential policymakers.
2024 was a blast for this biotech. Now what?
Fresh from FDA approval for its stem-cell product for paediatric graft-versus-host disease, Mesoblast is pursuing consent for indications of heart disease and back pain.
Cash pours in for ASX gold miners
With prices at all time highs, ASX gold miners could soon be adding more than $1 billion a quarter to their coffers.
Traders panic as stocks, metals, crypto bleed
A global selloff is hitting markets hard after Trump’s tariffs, with Ethereum plunging and copper prices taking a dive.
Sleep device maker’s shares take tariff hit
The maker of sleep apnoea and other devices, Kiwi-based Fisher & Paykel Healthcare expects a Trump tariff hit because it manufactures in Mexico.
Guy on Rocks: Almonty Industries
Guy casts his gaze over Almonty Industries and two tungsten projects across Portugal and South Korea with great strategic importance.
Exploration maestro leads the band at Artemis
Pilbara gold explorer Artemis Resources has a new leader whose mine finding pedigree augurs well as it targets the next Hemi.
Original URL: https://www.themercury.com.au/business/stockhead/page/25